Biodel, Inc. (NASDAQ:BIOD)
| CAPS Rating |
|
|---|---|
| Open | $0.65 |
| Previous Close | $0.66 |
| Daily Range | $0.62 - $0.65 |
| 52-Week Range | $0.50 - $2.59 |
| Market Cap | $24.71M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 283,007 |
| Average Daily Volume | 0 |
BIOD
VS S&P 500 (SPY)
How do you think BIOD will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BIOD Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BIOD News and Commentary
- Future Biotech Superstars – SeekingAlpha
- 4 Small Stocks with Buyout Rumors – NASDAQ
- Our Investor Outlook: Cautious and Protected – SeekingAlpha
- 5 Potentially Big Gainers Under $5 – SeekingAlpha
- 5 Top Stocks Under $5 – NASDAQ
- Biodel Aims Funding At Fast-Acting Diabetes Drugs; Shares Fall – SmartMoney
- Are These 8 Hated Stocks Ready to Pop? – SeekingAlpha
- Biotech’s Top and Bottom 10 From 2010 – SeekingAlpha
- U.S. Pharma: Latest Analyst Actions – SeekingAlpha
- The Big Money Says to Sell MannKind – The Motley Fool
- FDA Rejects Biodel’s Diabetes Drug: Biotech's Latest Mishaps – SeekingAlpha
- Analyst Calls: ARO, BA, BKE, DWA, MRVL, SGEN, TWC, WFR ... – BloggingStocks
- Closing Bell: Pre-Election Glee Turns Mixed (ABK, BHI, BIOD, JKS, XCO, FTNT, JPM) – BloggingStocks
- Wall Street Breakfast: Must-Know News – SeekingAlpha
- FDA Gives Treats to a Few Drugmakers – The Motley Fool
- Will These Drugs Get Past the FDA? – The Motley Fool
- 5 High-Impact Biotech Catalysts to Watch This Week – SeekingAlpha
- Friday Options Recap – SeekingAlpha
- Biodel: Upside from Potential Linjeta Approval – SeekingAlpha
- Sanofi-Aventis Seeks the Holy Grail of Insulin – SeekingAlpha
RSS Headlines
Fool UK
